Cancer Gene Therapy-Europe Market Status and Trend Report 2013-2023
Report Summary
Cancer Gene Therapy-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Cancer Gene Therapy industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Cancer Gene Therapy 2013-2017, and development forecast 2018-2023
Main market players of Cancer Gene Therapy in Europe, with company and product introduction, position in the Cancer Gene Therapy market
Market status and development trend of Cancer Gene Therapy by types and applications
Cost and profit status of Cancer Gene Therapy, and marketing status
Market growth drivers and challenges
The report segments the Europe Cancer Gene Therapy market as:
Europe Cancer Gene Therapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Cancer Gene Therapy Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Gene Induced Immunotherapy
Oncolytic Virotherapy
Gene Transfer
Europe Cancer Gene Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Diagnostics Centers
Research Institutes
Europe Cancer Gene Therapy Market: Players Segment Analysis (Company and Product introduction, Cancer Gene Therapy Sales Volume, Revenue, Price and Gross Margin):
Adaptimmune
GlaxoSmithKline
Bluebird bio
Merck
Celgene
Shanghai Sunway Biotech
BioCancell
Shenzhen SiBiono GeneTech
SynerGene Therapeutics
OncoGenex Pharmaceuticals
Genelux Corporation
Cell Genesys
Advantagene
GenVec
BioCancell
Celgene
Epeius Biotechnologies
Introgen Therapeutics
Ziopharm Oncology
Shenzhen SiBiono GeneTech
Altor Bioscience
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Cancer Gene Therapy-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Cancer Gene Therapy industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Cancer Gene Therapy 2013-2017, and development forecast 2018-2023
Main market players of Cancer Gene Therapy in Europe, with company and product introduction, position in the Cancer Gene Therapy market
Market status and development trend of Cancer Gene Therapy by types and applications
Cost and profit status of Cancer Gene Therapy, and marketing status
Market growth drivers and challenges
The report segments the Europe Cancer Gene Therapy market as:
Europe Cancer Gene Therapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Cancer Gene Therapy Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Gene Induced Immunotherapy
Oncolytic Virotherapy
Gene Transfer
Europe Cancer Gene Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Diagnostics Centers
Research Institutes
Europe Cancer Gene Therapy Market: Players Segment Analysis (Company and Product introduction, Cancer Gene Therapy Sales Volume, Revenue, Price and Gross Margin):
Adaptimmune
GlaxoSmithKline
Bluebird bio
Merck
Celgene
Shanghai Sunway Biotech
BioCancell
Shenzhen SiBiono GeneTech
SynerGene Therapeutics
OncoGenex Pharmaceuticals
Genelux Corporation
Cell Genesys
Advantagene
GenVec
BioCancell
Celgene
Epeius Biotechnologies
Introgen Therapeutics
Ziopharm Oncology
Shenzhen SiBiono GeneTech
Altor Bioscience
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF CANCER GENE THERAPY
1.1 Definition of Cancer Gene Therapy in This Report
1.2 Commercial Types of Cancer Gene Therapy
1.2.1 Gene Induced Immunotherapy
1.2.2 Oncolytic Virotherapy
1.2.3 Gene Transfer
1.3 Downstream Application of Cancer Gene Therapy
1.3.1 Hospitals
1.3.2 Diagnostics Centers
1.3.3 Research Institutes
1.4 Development History of Cancer Gene Therapy
1.5 Market Status and Trend of Cancer Gene Therapy 2013-2023
1.5.1 Europe Cancer Gene Therapy Market Status and Trend 2013-2023
1.5.2 Regional Cancer Gene Therapy Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Cancer Gene Therapy in Europe 2013-2017
2.2 Consumption Market of Cancer Gene Therapy in Europe by Regions
2.2.1 Consumption Volume of Cancer Gene Therapy in Europe by Regions
2.2.2 Revenue of Cancer Gene Therapy in Europe by Regions
2.3 Market Analysis of Cancer Gene Therapy in Europe by Regions
2.3.1 Market Analysis of Cancer Gene Therapy in Germany 2013-2017
2.3.2 Market Analysis of Cancer Gene Therapy in United Kingdom 2013-2017
2.3.3 Market Analysis of Cancer Gene Therapy in France 2013-2017
2.3.4 Market Analysis of Cancer Gene Therapy in Italy 2013-2017
2.3.5 Market Analysis of Cancer Gene Therapy in Spain 2013-2017
2.3.6 Market Analysis of Cancer Gene Therapy in Benelux 2013-2017
2.3.7 Market Analysis of Cancer Gene Therapy in Russia 2013-2017
2.4 Market Development Forecast of Cancer Gene Therapy in Europe 2018-2023
2.4.1 Market Development Forecast of Cancer Gene Therapy in Europe 2018-2023
2.4.2 Market Development Forecast of Cancer Gene Therapy by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Cancer Gene Therapy in Europe by Types
3.1.2 Revenue of Cancer Gene Therapy in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Cancer Gene Therapy in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Cancer Gene Therapy in Europe by Downstream Industry
4.2 Demand Volume of Cancer Gene Therapy by Downstream Industry in Major Countries
4.2.1 Demand Volume of Cancer Gene Therapy by Downstream Industry in Germany
4.2.2 Demand Volume of Cancer Gene Therapy by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Cancer Gene Therapy by Downstream Industry in France
4.2.4 Demand Volume of Cancer Gene Therapy by Downstream Industry in Italy
4.2.5 Demand Volume of Cancer Gene Therapy by Downstream Industry in Spain
4.2.6 Demand Volume of Cancer Gene Therapy by Downstream Industry in Benelux
4.2.7 Demand Volume of Cancer Gene Therapy by Downstream Industry in Russia
4.3 Market Forecast of Cancer Gene Therapy in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CANCER GENE THERAPY
5.1 Europe Economy Situation and Trend Overview
5.2 Cancer Gene Therapy Downstream Industry Situation and Trend Overview
CHAPTER 6 CANCER GENE THERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Cancer Gene Therapy in Europe by Major Players
6.2 Revenue of Cancer Gene Therapy in Europe by Major Players
6.3 Basic Information of Cancer Gene Therapy by Major Players
6.3.1 Headquarters Location and Established Time of Cancer Gene Therapy Major Players
6.3.2 Employees and Revenue Level of Cancer Gene Therapy Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 CANCER GENE THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Adaptimmune
7.1.1 Company profile
7.1.2 Representative Cancer Gene Therapy Product
7.1.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Adaptimmune
7.2 GlaxoSmithKline
7.2.1 Company profile
7.2.2 Representative Cancer Gene Therapy Product
7.2.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.3 Bluebird bio
7.3.1 Company profile
7.3.2 Representative Cancer Gene Therapy Product
7.3.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Bluebird bio
7.4 Merck
7.4.1 Company profile
7.4.2 Representative Cancer Gene Therapy Product
7.4.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Merck
7.5 Celgene
7.5.1 Company profile
7.5.2 Representative Cancer Gene Therapy Product
7.5.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Celgene
7.6 Shanghai Sunway Biotech
7.6.1 Company profile
7.6.2 Representative Cancer Gene Therapy Product
7.6.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Shanghai Sunway Biotech
7.7 BioCancell
7.7.1 Company profile
7.7.2 Representative Cancer Gene Therapy Product
7.7.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of BioCancell
7.8 Shenzhen SiBiono GeneTech
7.8.1 Company profile
7.8.2 Representative Cancer Gene Therapy Product
7.8.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Shenzhen SiBiono GeneTech
7.9 SynerGene Therapeutics
7.9.1 Company profile
7.9.2 Representative Cancer Gene Therapy Product
7.9.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of SynerGene Therapeutics
7.10 OncoGenex Pharmaceuticals
7.10.1 Company profile
7.10.2 Representative Cancer Gene Therapy Product
7.10.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of OncoGenex Pharmaceuticals
7.11 Genelux Corporation
7.11.1 Company profile
7.11.2 Representative Cancer Gene Therapy Product
7.11.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Genelux Corporation
7.12 Cell Genesys
7.12.1 Company profile
7.12.2 Representative Cancer Gene Therapy Product
7.12.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Cell Genesys
7.13 Advantagene
7.13.1 Company profile
7.13.2 Representative Cancer Gene Therapy Product
7.13.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Advantagene
7.14 GenVec
7.14.1 Company profile
7.14.2 Representative Cancer Gene Therapy Product
7.14.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of GenVec
7.15 BioCancell
7.15.1 Company profile
7.15.2 Representative Cancer Gene Therapy Product
7.15.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of BioCancell
7.16 Celgene
7.17 Epeius Biotechnologies
7.18 Introgen Therapeutics
7.19 Ziopharm Oncology
7.20 Shenzhen SiBiono GeneTech
7.21 Altor Bioscience
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER GENE THERAPY
8.1 Industry Chain of Cancer Gene Therapy
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CANCER GENE THERAPY
9.1 Cost Structure Analysis of Cancer Gene Therapy
9.2 Raw Materials Cost Analysis of Cancer Gene Therapy
9.3 Labor Cost Analysis of Cancer Gene Therapy
9.4 Manufacturing Expenses Analysis of Cancer Gene Therapy
CHAPTER 10 MARKETING STATUS ANALYSIS OF CANCER GENE THERAPY
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Cancer Gene Therapy in This Report
1.2 Commercial Types of Cancer Gene Therapy
1.2.1 Gene Induced Immunotherapy
1.2.2 Oncolytic Virotherapy
1.2.3 Gene Transfer
1.3 Downstream Application of Cancer Gene Therapy
1.3.1 Hospitals
1.3.2 Diagnostics Centers
1.3.3 Research Institutes
1.4 Development History of Cancer Gene Therapy
1.5 Market Status and Trend of Cancer Gene Therapy 2013-2023
1.5.1 Europe Cancer Gene Therapy Market Status and Trend 2013-2023
1.5.2 Regional Cancer Gene Therapy Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Cancer Gene Therapy in Europe 2013-2017
2.2 Consumption Market of Cancer Gene Therapy in Europe by Regions
2.2.1 Consumption Volume of Cancer Gene Therapy in Europe by Regions
2.2.2 Revenue of Cancer Gene Therapy in Europe by Regions
2.3 Market Analysis of Cancer Gene Therapy in Europe by Regions
2.3.1 Market Analysis of Cancer Gene Therapy in Germany 2013-2017
2.3.2 Market Analysis of Cancer Gene Therapy in United Kingdom 2013-2017
2.3.3 Market Analysis of Cancer Gene Therapy in France 2013-2017
2.3.4 Market Analysis of Cancer Gene Therapy in Italy 2013-2017
2.3.5 Market Analysis of Cancer Gene Therapy in Spain 2013-2017
2.3.6 Market Analysis of Cancer Gene Therapy in Benelux 2013-2017
2.3.7 Market Analysis of Cancer Gene Therapy in Russia 2013-2017
2.4 Market Development Forecast of Cancer Gene Therapy in Europe 2018-2023
2.4.1 Market Development Forecast of Cancer Gene Therapy in Europe 2018-2023
2.4.2 Market Development Forecast of Cancer Gene Therapy by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Cancer Gene Therapy in Europe by Types
3.1.2 Revenue of Cancer Gene Therapy in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Cancer Gene Therapy in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Cancer Gene Therapy in Europe by Downstream Industry
4.2 Demand Volume of Cancer Gene Therapy by Downstream Industry in Major Countries
4.2.1 Demand Volume of Cancer Gene Therapy by Downstream Industry in Germany
4.2.2 Demand Volume of Cancer Gene Therapy by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Cancer Gene Therapy by Downstream Industry in France
4.2.4 Demand Volume of Cancer Gene Therapy by Downstream Industry in Italy
4.2.5 Demand Volume of Cancer Gene Therapy by Downstream Industry in Spain
4.2.6 Demand Volume of Cancer Gene Therapy by Downstream Industry in Benelux
4.2.7 Demand Volume of Cancer Gene Therapy by Downstream Industry in Russia
4.3 Market Forecast of Cancer Gene Therapy in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CANCER GENE THERAPY
5.1 Europe Economy Situation and Trend Overview
5.2 Cancer Gene Therapy Downstream Industry Situation and Trend Overview
CHAPTER 6 CANCER GENE THERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Cancer Gene Therapy in Europe by Major Players
6.2 Revenue of Cancer Gene Therapy in Europe by Major Players
6.3 Basic Information of Cancer Gene Therapy by Major Players
6.3.1 Headquarters Location and Established Time of Cancer Gene Therapy Major Players
6.3.2 Employees and Revenue Level of Cancer Gene Therapy Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 CANCER GENE THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Adaptimmune
7.1.1 Company profile
7.1.2 Representative Cancer Gene Therapy Product
7.1.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Adaptimmune
7.2 GlaxoSmithKline
7.2.1 Company profile
7.2.2 Representative Cancer Gene Therapy Product
7.2.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.3 Bluebird bio
7.3.1 Company profile
7.3.2 Representative Cancer Gene Therapy Product
7.3.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Bluebird bio
7.4 Merck
7.4.1 Company profile
7.4.2 Representative Cancer Gene Therapy Product
7.4.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Merck
7.5 Celgene
7.5.1 Company profile
7.5.2 Representative Cancer Gene Therapy Product
7.5.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Celgene
7.6 Shanghai Sunway Biotech
7.6.1 Company profile
7.6.2 Representative Cancer Gene Therapy Product
7.6.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Shanghai Sunway Biotech
7.7 BioCancell
7.7.1 Company profile
7.7.2 Representative Cancer Gene Therapy Product
7.7.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of BioCancell
7.8 Shenzhen SiBiono GeneTech
7.8.1 Company profile
7.8.2 Representative Cancer Gene Therapy Product
7.8.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Shenzhen SiBiono GeneTech
7.9 SynerGene Therapeutics
7.9.1 Company profile
7.9.2 Representative Cancer Gene Therapy Product
7.9.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of SynerGene Therapeutics
7.10 OncoGenex Pharmaceuticals
7.10.1 Company profile
7.10.2 Representative Cancer Gene Therapy Product
7.10.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of OncoGenex Pharmaceuticals
7.11 Genelux Corporation
7.11.1 Company profile
7.11.2 Representative Cancer Gene Therapy Product
7.11.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Genelux Corporation
7.12 Cell Genesys
7.12.1 Company profile
7.12.2 Representative Cancer Gene Therapy Product
7.12.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Cell Genesys
7.13 Advantagene
7.13.1 Company profile
7.13.2 Representative Cancer Gene Therapy Product
7.13.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of Advantagene
7.14 GenVec
7.14.1 Company profile
7.14.2 Representative Cancer Gene Therapy Product
7.14.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of GenVec
7.15 BioCancell
7.15.1 Company profile
7.15.2 Representative Cancer Gene Therapy Product
7.15.3 Cancer Gene Therapy Sales, Revenue, Price and Gross Margin of BioCancell
7.16 Celgene
7.17 Epeius Biotechnologies
7.18 Introgen Therapeutics
7.19 Ziopharm Oncology
7.20 Shenzhen SiBiono GeneTech
7.21 Altor Bioscience
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER GENE THERAPY
8.1 Industry Chain of Cancer Gene Therapy
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CANCER GENE THERAPY
9.1 Cost Structure Analysis of Cancer Gene Therapy
9.2 Raw Materials Cost Analysis of Cancer Gene Therapy
9.3 Labor Cost Analysis of Cancer Gene Therapy
9.4 Manufacturing Expenses Analysis of Cancer Gene Therapy
CHAPTER 10 MARKETING STATUS ANALYSIS OF CANCER GENE THERAPY
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
